Recent discovery and development of inhibitors targeting coronaviruses

Drug Discov Today. 2020 Apr;25(4):668-688. doi: 10.1016/j.drudis.2020.01.015. Epub 2020 Jan 30.

Abstract

Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded RNA genome. Currently, six human CoVs have been reported including human coronavirus 229E (HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome (MERS) coronavirus (MERS-CoV). They cause moderate to severe respiratory and intestinal infections in humans. In this review, we focus on recent advances in the research and development of small-molecule anti-human coronavirus therapies targeting different stages of the CoV life cycle.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiviral Agents / adverse effects
  • Antiviral Agents / chemistry
  • Antiviral Agents / therapeutic use*
  • Coronaviridae Infections / diagnosis
  • Coronaviridae Infections / drug therapy*
  • Coronaviridae Infections / virology
  • Coronavirus / drug effects*
  • Coronavirus / growth & development
  • Coronavirus / pathogenicity
  • Drug Design*
  • Drug Development*
  • Humans
  • Molecular Structure
  • Molecular Targeted Therapy*
  • Structure-Activity Relationship

Substances

  • Antiviral Agents